

**Date: 5/2/1432H (9/1/2011)**

**Subject: Fees of Inspection Services of Human Drugs Manufacturers**

To: General Director of the Company

To: Scientific Office Manager

Dear Gentlemen,

Referring to circular No. 2058 dated on 25/8/1430H which was announced to all Pharmaceutical companies and Scientific Offices regarding the fees of the inspection visits to drug manufacturer, and after reevaluating the fees:

We would like to inform you that according to the fourth article of the Saudi Food & Drug Authority regulation which was issued by the Royal act number (6) on (25/1/1428 H), “*the SFDA has the right to perform its tasks commercially with all necessary permissions to perform its tasks.*” In addition to section No. 16 of the Authority’s regulation that is related to its financial sources including the income it generates from the provided services to the beneficiaries, and to the jurisdictions of His Excellency the CEO of SFDA. Therefore, the fees of Inspection Services have been approved by administrative decision No. (13/32) dated on 21/1/1432H according to the attached table. The payment of the fees shall be done through the SFDA account by the (SADAD) system.

Thank you for your corporation

***Signed by***

Vice-President for Drug Affairs

Prof. Saleh Abdullah Bawazir

**Attached table:**

The fees of inspection services:

1. The SFDA shall charge the fees of inspection services from the pharmaceutical establishments (Manufactures of Pharmaceutical Products, Laboratories, Bio-equivalence centers and Clinical trials centers) according to the following table:

| No. | Location                                                                                            | Fees by Saudi Riyal |
|-----|-----------------------------------------------------------------------------------------------------|---------------------|
| 1.  | Saudi Arabia                                                                                        | 33,000              |
| 2.  | Arab countries, <b>Group 1:</b><br>The GCC Countries, Yemen, Iraq, Jordan, Syria, Lebanon and Egypt | 61,000              |
| 3.  | Arab countries, <b>Group 2:</b><br>Libya, Algeria, Tunisia, Morocco                                 | 88,000              |
| 4.  | Africa                                                                                              | 88,000              |
| 5.  | Europe & Turkey                                                                                     | 121,000             |
| 6.  | South East Asia:<br>Malaysia, Singapore, India, Pakistan, Iran, Thailand, Philippines.              | 80,000              |
| 7.  | North and South America                                                                             | 161,000             |
| 8.  | China, Korea and Central Asian Republics                                                            | 103,000             |
| 9.  | Japan and Russia                                                                                    | 147,000             |
| 10. | Australia and New Zealand                                                                           | 184,000             |

2. The same amount of fees will be charged when revisiting.
3. This act is active from the date of its issue, and revoke the other circular No. 2058 dated 25/8/1430H.